| Title |
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy
|
|---|---|
| Published in |
Drugs, December 2017
|
| DOI | 10.1007/s40265-017-0855-5 |
| Pubmed ID | |
| Authors |
Emma D. Deeks |
| Abstract |
Fulvestrant (Faslodex®), a selective estrogen receptor (ER) degrader, is now indicated for the treatment of ER+ or hormone-receptor positive (HR+)/HER2- advanced breast cancer in postmenopausal women previously untreated with endocrine therapy. In the phase 3 FALCON trial conducted in this setting, intramuscular fulvestrant 500 mg/month (plus an additional dose at 2 weeks) was significantly more effective in prolonging progression-free survival (PFS) than oral anastrozole 1 mg/day (particularly in patients with non-visceral disease), with this benefit seemingly driven by fulvestrant recipients responding significantly longer to treatment. Other efficacy measures, including objective response rate, did not significantly or markedly differ between the two regimens and median overall survival was not yet calculable. Fulvestrant was generally well tolerated in this trial, displaying an overall tolerability profile consistent with its known tolerability in other breast cancer settings. Thus, monotherapy with intramuscular fulvestrant is a generally well tolerated and more effective treatment option than standard-of-care anastrozole for ER+ or HR+/HER2- advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 17% |
| Other | 2 | 11% |
| Librarian | 1 | 6% |
| Student > Ph. D. Student | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 8 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 17% |
| Medicine and Dentistry | 3 | 17% |
| Agricultural and Biological Sciences | 2 | 11% |
| Psychology | 1 | 6% |
| Engineering | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 8 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2017.
All research outputs
#18,581,651
of 23,015,156 outputs
Outputs from Drugs
#3,019
of 3,287 outputs
Outputs of similar age
#328,891
of 440,666 outputs
Outputs of similar age from Drugs
#26
of 27 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,666 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.